Macrophage scavenger receptors
Brief biographies of the "classical" macrophage scavenger receptors
In this section we will briefly introduce the senior members of the macrophage scavenger receptor family, highlighting recent insights into their biology and newly identified ligands. For more comprehensive descriptions the reader is referred to more comprehensive reviews e.g. In 1993 CD36 was shown to bind and internalise minimally modified forms of LDL [34] and peritoneal macrophages of CD-36 knockout mice exhibit a 60-80% decrease in both oxLDL binding and oxLDL uptake [35] . The importance of CD36 as a receptor for modified LDL in vivo was confirmed when CD36-/-mice were crossed with apoE-/-mice resulting in a 70% reduction in atherosclerotic lesion size in animals fed a high fat diet [36] . This work has been confirmed and extended by the analysis of apoE-/-reconstituted with macrophages deficient in CD36 expression [37] . There have been a number of reports implicating SR-A in adaptive immunity, most recently including a report that SR-A may be involved in the capture of antigen from live cells by a process of "antigen nibbling" [75] . While yet to be critically evaluated for their role in antigen capture and processing, the expression of scavenger receptors by dendritic cell populations hints at scavenger receptor functions in adaptive immunity as well as their role in the innate immune system and the arterial wall. Macrophage scavenger receptors cell surface [88] . In addition to acting as a membrane receptor for oxLDL, soluble forms of LOX-1 have been identified, which are secreted by TNF-α stimulated endothelial cells [89] .
Cells transfected with a LOX-1 expression vector support the binding and internalisation of oxLDL [90] and LOX-1 will bind a range of other ligands including activated platelets, gram positive and gram negative bacteria and apoptotic cells (reviewed in [91, 92] ). Although originally described as an endothelial cell scavenger receptor, LOX-1 is expressed by macrophages and vascular smooth muscle cells [93] . An immunohistochemical analysis of human atherosclerotic lesions has shown that endothelial cells associated with early atherosclerotic lesions express LOX-1 but in more advanced lesions vascular SMCs and lipid laden macrophages express readily detectable levels of LOX-1 [94] . A definitive assessment of the role of LOX-1 in atherogenesis awaits the development of LOX-1 knockout mice.
Recent additions to the macrophage scavenger receptor family
Despite the identification and detailed characterisation of CD36, SR-A, LOX-1 and SR-BI, examination of non-macrophage cell type uptake of modified LDL combined with expression cloning and genomic approaches have yielded several new cell surface receptors capable of specifically binding modified LDL. We have singled out some of the more recent interesting additions to the macrophage scavenger receptor family for further discussion.
SR-PSOX (CXCL16)
The macrophage scavenger receptor SR-PSOX was identified by an expression cloning strategy using a cDNA library generated from mRNA of THP-1 cells transfected into COS-7 cells and screened using DiI-labelled oxLDL [95] .
Human SR-PSOX (scavenger receptor that binds phosphatidylserine and oxidised lipoprotein) is a type I membrane protein of 254 amino acids that shows no homology 12.
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Macrophage scavenger receptors with other scavenger receptors. The transfected hSR-PSOX gene directs expression of a 30kDa protein that can bind 125 I-oxLDL with a similar affinity to that of other scavenger receptors. Two years after the original identification of SR-PSOX it was shown to be identical to an unusual membrane bound CXC chemokine called CXCL16 [96, 97] .
Recent reports have shown that SR-PSOX/CXCL16 mediates binding and phagocytosis of Gram-negative and Gram-positive bacteria and this binding activity maps to the chemokine domain, which is also responsible for the recognition of oxLDL [98, 99] . SREC-1 only 6% of total macrophage acLDL degradation [107] . The availability of SREC-I knockout mice will allow for a direct assessment of the role of SREC-I in murine models of atherogenesis and will aid in the search for specific SREC-I and SREC-II ligands [108] as well as a re-examination of the role of SREC-I in cell adhesion and cell morphology [109] .
CD163
Tissue macrophages remove haemoglobin produced by lysis of erythrocytes in a complex with haptoglobin via a cell surface receptor containing nine tandem scavenger receptor cysteine-rich (SRCR) domains. This macrophage receptor was identified as the CD163 differentiation antigen, which is expressed at a high level by tissue resident macrophages and its expression level can be further augmented by glucocorticoids and the cytokines Interleukin-10 and Interleukin-6 (which also increases haptoglobin synthesis) [110] . While there are no reports of CD163 binding modified LDL, the macrophage scavenger for haemoglobin CD163 serves to remind us that tissue resident macrophages have evolved a wide range of endocytic receptors designed to scavenge or clear potentially harmful products of host origin including but not limited to modified LDL. Elevated serum levels of soluble CD163 shed from activated macrophages has been observed in patients with rheumatoid arthritis [111] and CD163-mediated clearance of modified forms of haemoglobin may be important in atherogenesis in diabetic subjects [112] .
14. 217G8E9 [114] . This result strongly suggests that the anti Ptdsr mAb recognises at least two different proteins one of which is critically important for apoptotic cell recognition and remains to be identified.
Towards a new definition of macrophage scavenger receptors?
With so many cell surface receptors displaying some aspects of scavenger receptor activity do we need to tighten our definition of macrophage scavenger receptors? Macrophage scavenger receptors
Unanswered questions
• Are there more macrophage scavenger receptors waiting to be discovered? There are probably a few more members of the scavenger receptor family still to be identified. One obvious candidate is the receptor recognised by the "phosphatidylserine receptor" monoclonal antibody that blocks macrophage uptake of apoptotic cells. There are probably several new scavenger receptor ligands to be characterised, including several encoded by microbial pathogens and the cellular and extracellular substrates for macrophage adhesion.
• Are there anatomical sites other than the arterial wall where we should be looking for new biological activities of macrophage scavenger receptors? Potentially interesting sites to look for macrophage scavenger receptor function would include adipose tissue [125] , lymphatic endothelium [126] and sites of microglia activation and macrophage recruitment in neuropathologies including
Alzheimer's disease [127] .
• What role do macrophage scavenger receptors play in antigen presentation and elaboration of an adaptive immune response? A potential role for scavenger receptors in adaptive immunity is hinted at by the role of apoptotic cell phagocytosis in antigen cross priming [43] and the expression of SR-A on dendritic cells [75] .
• Is heterogeneity in scavenger receptor expression in vivo important in the biology of tissue resident macrophages and DCs? A better picture of macrophage heterogeneity with respect to scavenger receptor expression and function will require the development of better antibodies for use in histochemistry and more
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Macrophage scavenger receptors detailed phenotyping of receptor knockout mice. Recent studies by Geissman et al. [128] have suggested that monocytes in blood are heterogeneous with regard to their surface phenotype (CX3CR1 and CCR2 expression as well as CD14, CD16
antigens), which can be correlated with their ability to be recruited by inflammatory stimuli or constitutively to peripheral tissues. It is not known whether recruitment to the arterial wall selects for a similar subpopulation of monocytes as infectious or physiologic stimuli. Normal circulating monocytes do not express SR-A but experimental models with fluorescent markers for different receptors now make it possible to approach this question experimentally [129] .
Future prospects
Despite their central role in atherogenesis, we have not yet been able to exploit our knowledge of scavenger receptor biology to develop better treatments for cardiovascular disease. Such a goal may seem unrealistic given the multiplicity of scavenger receptors and their ligands, but the emerging worldwide epidemic of Type II diabetes and the continuing burden of cardiovascular disease argue strongly that we need to improve our knowledge of these receptors if we are to develop a better understanding of the pathological processes that drive the development of atherosclerotic plaques and diabetic vasculopathy.
